Characterization of the human kinetic adjustment factor for the health risk assessment of environmental contaminants

Journal of Applied Toxicology

Volumn 34, Issue 3, 2014, Pages 227-240

  Valcke, Mathieu ^a,b   Krishnan, Kannan ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

Environmental contaminants; Exposure conditions; Human kinetic adjustment factor (HKAF); Interindividual variability; Monte Carlo simulations; Phase I metabolism; Physiologically based pharmacokinetic (PBPK) modeling; Risk assessment; Steady state solutions; Toxicokinetics

Indexed keywords

BROMOFORM; CHLOROFORM; CYTOCHROME P450 1A2; CYTOCHROME P450 2E1; DICHLOROMETHANE; NICOTINE; TETRACHLOROETHYLENE; TRICHLOROETHYLENE; VINYL CHLORIDE; VOLATILE ORGANIC COMPOUND; XENOBIOTIC AGENT;

AREA UNDER THE CURVE; ARTICLE; DRUG CLEARANCE; ENVIRONMENTAL EXPOSURE; HEALTH HAZARD; HUMAN; INGESTION; INHALATION; LIVER CLEARANCE; LIVER WEIGHT; LONG TERM EXPOSURE; METABOLITE; MONTE CARLO METHOD; POLLUTANT; PREGNANT WOMAN; PRIORITY JOURNAL; PUBLIC HEALTH; RISK ASSESSMENT; STEADY STATE; TOXICOKINETICS;

ENVIRONMENTAL CONTAMINANTS; EXPOSURE CONDITIONS; HUMAN KINETIC ADJUSTMENT FACTOR (HKAF); INTERINDIVIDUAL VARIABILITY; MONTE CARLO SIMULATIONS; PHASE I METABOLISM; PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING; RISK ASSESSMENT; STEADY-STATE SOLUTIONS; TOXICOKINETICS;

AGE FACTORS; ANIMALS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTANTS; HUMANS; METABOLIC DETOXICATION, PHASE I; METABOLIC DETOXICATION, PHASE II; MODELS, BIOLOGICAL; PUBLIC HEALTH; RISK ASSESSMENT; UNCERTAINTY;

EID: 84892991725     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.2919     Document Type: Article

References (102)

1. Abraham K, Mielke H, Huisinga W, Gundert-Remy U. 2005. Elevated internal exposure of children in simulated acute inhalation of volatile organic compounds: effects of concentration and duration. Arch. Toxicol. 79: 63-73.
2. Andersen ME. 1981. A physiologically based toxicokinetic description of the metabolism of inhaled gases and vapors: analysis at steady state. Toxicol. Appl. Pharmacol. 60: 509-526.
3. Beaudouin R, Micallef S, Brochot C. 2010. A stochastic whole-body physiologically based pharmacokinetic model to assess the impact of inter-individual variability on tissue dosimetry over the human lifespan. Regul. Toxicol. Pharmacol. 57: 103-116.
4. Beck B, Mattuck RL, Bowers TS. 2002. Adult-child differences in the intraspecies uncertainty factor: a case study using lead. Hum. Ecol. Risk Assess. 8: 877-884.
5. Blackburn AC, Tzeng HF, Anders MW, Board PG. 2000. Discovery of a functional polymorphism in human glutathione transferase zeta by expressed sequence tag database analysis. Pharmacogenetics 10: 49-57.
6. Bogaards JJP, Hissink EM, Briggs M, Weaver R, Jochemsen R, Jackson P, Bertrand M, van Bladeren PJ. 2000. Prediction of interindividual variation in drug plasma levels in vivo from enzyme kinetic data and physiologically based pharmacokinetic modeling. Eur. J. Pharm. Sci. 12: 117-124.
7. Bois FY, Jackson ET, Pekari K, Smith MT. 1996. Population toxicokinetics of benzene. Environ. Health Perspect. 104(Suppl 6): 1405-1411.
8. Brent RL. 2004. Utilization of juvenile animal studies to determine the human effects and risks of environmental toxicants during postnatal developmental stages. Birth Defects Res. B Dev. Reprod. Toxicol. 71: 303-320.
9. Caldwell JC, Evans MV, Krishnan K. 2012. Cutting edge PBPK models and analyses: providing the basis for future modeling efforts and bridges to emerging toxicology paradigms. J. Toxicol. doi:10.1155/2012/852384.
10. CALEPA (California Environmental Protection Agency). 2009. Public Health Goal for Trichloroethylene in Drinking Water. In Pesticide and Environmental Toxicology Branch OoEHRAH (ed). California Environmental Protection Agency.
11. Chiu WA, White P. 2006. Steady-state solutions to PBPK models and their applications to risk assessment I: Route-to-route extrapolation of volatile chemicals. Risk Anal. 26: 769-780.
12. Chiu WA, Okino MS, Evans MV. 2009. Characterizing uncertainty and population variability in the toxicokinetics of trichloroethylene and metabolites in mice, rats, and humans using an updated database, physiologically based pharmacokinetic (PBPK) model, and Bayesian approach. Toxicol. Appl. Pharmacol. 241: 36-60.
13. Clewell HJ, Gearhart JM, Gentry PR, Covington TR, VanLandingham CB, Crump KS, Shipp AM. 1999. Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. Risk Anal. 19: 547-558.
14. Clewell HJ, Teeguarden J, McDonald T, Sarangapani R, Lawrence G, Covington T, Gentry R, Shipp A. 2002. Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Crit. Rev. Toxicol. 32: 329-389.
15. Clewell HJ, Gentry PR, Covington TR, Sarangapani R, Teeguarden JG. 2004. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol. Sci. 79: 381-393.
16. Covington TR, Robinan GP, Van Landingham CB, Andersen ME, Kester JE, Clewell HJ. 2007. The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene. Regul. Toxicol. Pharmacol. 47: 1-18.
17. Crump KS, Chiu WA, Subramaniam RP. 2010. Issues in using human variability distributions to estimate low-dose risk. Environ. Health Perspect. 118: 387-393.
18. Csanady GA, Filser JG. 2001. The relevance of physical activity for the kinetics of inhaled gaseous substances. Arch. Toxicol. 74: 663-672.
19. Delic JI, Lilly PD, MacDonald AJ, Loizou GD. 2000. The utility of PBPK in the safety assessment of chloroform and carbon tetrachloride. Regul. Toxicol. Pharmacol. 32: 144-155.
20. DeWoskin RS, Lipscomb JC, Thompson C, Chiu WA, Schlosser PM, Smallwood C, Swartout J, Teuschler LK, Marcus A. 2007. Pharmacokinetic/physiologically based pharmacokinetic models in integrated risk information system. In Toxicokinetics and Risk Assessment, Lipscomb JC, Ohanian E (eds). Informa Healthcare: New York; 301-348.
21. Dorne JL. 2007. Human variability in hepatic and renal elimination: implications for risk assessment. J. Appl. Toxicol. 27: 411-420.
22. Dorne JL, Renwick AG. 2005. The refinement of uncertainty/safety factors in risk assessment by the incorporation of data on toxicokinetic variability in humans. Toxicol. Sci. 86: 20-26.
23. Dorne JL, Walton K, Renwick AG. 2001a. Uncertainty factors for chemical risk assessment. Human variability in the pharmacokinetics of CYP1A2 probe substrates. Food Chem. Toxicol. 39: 681-696.
24. Dorne JL, Walton K, Renwick AG. 2001b. Human variability in glucuronidation in relation to uncertainty factors for risk assessment. Food Chem. Toxicol. 39: 1153-1173.
25. Dorne JL, Walton K, Slob W, Renwick AG. 2002. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? Food Chem. Toxicol. 40: 1633-1656.
26. Dorne JL, Walton K, Renwick AG. 2003a. Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors. Food Chem. Toxicol. 41: 225-245.
27. Dorne JL, Walton K, Renwick AG. 2003b. Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. Food Chem. Toxicol. 41: 201-224.
28. Dorne JL, Walton K, Renwick AG. 2004a. Human variability in the renal elimination of foreign compounds and renal excretion-related uncertainty factors for risk assessment. Food Chem. Toxicol. 42: 275-298.
29. Dorne JL, Walton K, Renwick AG. 2004b. Human variability for metabolic pathways with limited data (CYP2A6, CYP2C9, CYP2E1, ADH, esterases, glycine and sulphate conjugation). Food Chem. Toxicol. 42: 397-421.
30. Dorne JL, Walton K, Renwick AG. 2005. Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review. Food Chem. Toxicol. 43: 203-216.
31. Dourson ML, Felter SP, Robinson D. 1996. Evolution of science-based uncertainty factors in noncancer risk assessment. Regul. Toxicol. Pharmacol. 24: 108-120.
32. Dourson ML, Stara JF. 1983. Regulatory history and experimental support of uncertainty (safety) factors. Regul. Toxicol. Pharmacol. 3: 224-238.
33. El-Masri HA, Bell DA, Portier CJ. 1999. Effects of glutathione transferase theta polymorphism on the risk estimates of dichloromethane to humans. Toxicol. Appl. Pharmacol. 158: 221-230.
34. Gentry PR, Hack CE, Haber L, Maier A, Clewell HJ, III. 2002. An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: examples with warfarin and parathion. Toxicol. Sci. 70: 120-139.
35. Ginsberg G, Hattis D, Sonawane B, Russ A, Banati P, Kozlak M, Smolenski S, Goble R. 2002a. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol. Sci. 66: 185-200.
36. Ginsberg G, Smolenski S, Hattis D, Sonawane B. 2002b. Population distribution of aldehyde dehydrogenase-2 genetic polymorphism: implications for risk assessment. Regul. Toxicol. Pharmacol. 36: 297-309.
37. Ginsberg G, Hattis D, Russ A, Sonawane B. 2004. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents. J. Toxicol. Environ. Health A 67: 297-329.
38. Ginsberg GL, Foos BP, Firestone MP. 2005. Review and analysis of inhalation dosimetry methods for application to children's risk assessment. J. Toxicol. Environ. Health A 68: 573-615.
39. Ginsberg G, Smolenski S, Neafsey P, Hattis D, Walker K, Guyton KZ, Johns DO, Sonawane B. 2009. The influence of genetic polymorphism on population variability in six xenobiotic-metabolizing enzymes. J. Toxicol. Environ. Health B 12: 307-333.
40. Hack CE, Chiu WA, Jay ZQ, Clewell HJ. 2006. Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites. Regul. Toxicol. Pharmacol. 46: 63-83.
41. Haddad S, Tardif GC, Tardif R. 2006. Development of physiologically based toxicokinetic models for improving the human indoor exposure assessment to water contaminants: trichloroethylene and trihalomethanes. J. Toxicol. Environ. Health A 69: 2095-2136.
42. Health Canada. 2005. Guidelines for Canadian Drinking Water Quality: Supporting Documentation-Trichloroethylene. Water Quality and Health Bureau HEaCSB (ed). Health Canada: Ottawa, ON, Canada.
43. Health Canada. 2006. Guidelines for Canadian Drinking Water Quality: Supporting Documentation-Trihalomethanes. Water Quality and Health Bureau HEaCSB (ed). Health Canada: Ottawa, ON, Canada.
44. Hines RN, Sargent D, Autrup H, Birnbaum LS, Brent RL, Doerrer NG, Cohen Hubal EA, Juberg DR, Laurent C, Luebke R, Olejniczak K, Portier CJ, Slikker W. 2010. Approaches for assessing risks to sensitive populations: lessons learned from evaluating risks in the pediatric population. Toxicol. Sci. 113: 4-26.
45. IPCS. 1994. Assessing human health risks of chemicals: Derivation of guidance values for health based exposure limits. International Panel on ChemicalSafety (ed). World Health Organization: Geneva.
46. Johnsrud EK, Koukouritaki SB, Divakaran K, Brunengraber LL, Hines RN, McCarver DG. 2003. Human hepatic CYP2E1 expression during development. J. Pharmacol. Exp. Ther. 307: 402-407.
47. Jonsson F, Johanson G. 2001a. A Bayesian analysis of the influence of GSTT1 polymorphism on the cancer risk estimate for dichloromethane. Toxicol. Appl. Pharmacol. 174: 99-112.
48. Jonsson F, Johanson G. 2001b. Bayesian estimation of variability in adipose tissue blood flow in man by physiologically based pharmacokinetic modeling of inhalation exposure to toluene. Toxicology 157: 177-193.
49. Jonsson F, Johanson G. 2002. Physiologically based modeling of the inhalation kinetics of styrene in humans using a bayesian population approach. Toxicol. Appl. Pharmacol. 179: 35-49.
50. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. 1997. Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur. J. Biochem. 247: 625-634.
51. Lapare S, Tardif R, Brodeur J. 1993. Effect of various exposure scenarios on the biological monitoring of organic solvents in alveolar air. I. Toluene and m-xylene. Int. Arch. Occup. Environ. Health 64: 569-580.
52. Lapare S, Tardif R, Brodeur J. 1995. Effect of various exposure scenarios on the biological monitoring of organic solvents in alveolar air. II. 1, 1, 1-Trichloroethane and trichloroethylene. Int. Arch. Occup. Environ. Health 67: 375-394.
53. Liao KH, Tan YM, Conolly RB, Borghoff SJ, Gargas ML, Andersen ME, Clewell HJ, III. 2007a. Bayesian estimation of pharmacokinetic and pharmacodynamic parameters in a mode-of-action-based cancer risk assessment for chloroform. Risk Anal. 27: 1535-1551.
54. Liao KH, Tan YM, Clewell HJ, III. 2007b. Development of a screening approach to interpret human biomonitoring data on volatile organic compounds: reverse dosimetry on biomonitoring data for trichloroethylene. Risk Anal. 27: 1223-1236.
55. Lin JH, Lu AY. 2001. Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Annu. Rev. Pharmacol. Toxicol. 41: 535-567.
56. Lipscomb JC, Teuschler LK, Swartout J, Swan GE, Snawder JE. 2003. Variance of microsomal protein and cytochrome P450 2E1 and 3A forms in adult human liver. Toxicol. Mech. Methods 13: 45-51.
57. McNally K, Cotton R, Cocker J, Jones K, Bartels M, Rick D, Price P, Loizou G. 2012. Reconstruction of Exposure to m-Xylene from Human Biomonitoring Data Using PBPK Modelling, Bayesian Inference, and Markov Chain Monte Carlo Simulation. J Toxicol 2012: 760281
58. Meek ME, Ohanian E, Renwick A, Naumann B, Lake B, Vu V, Dourson M. 1999. Guidelines for application of data-derived uncertainty factors in risk assessment. Report of a Meeting by Toxicology Excellence for Risk Assessment for US EPA/Health Canada, Washington, March 25th-26th.
59. Meek ME, Renwick A, Ohanian E, Dourson M, Lake B, Naumann BD, Vu V. 2002. Guidelines for application of chemical-specific adjustment factors in dose/concentration-response assessment. Toxicology 181-182: 115-120.
60. Mehendale HM. 1995. Toxicodynamics of low level toxicant interactions of biological significance: inhibition of tissue repair. Toxicology 105: 251-266.
61. Mielke H, Gundert A, Abraham K, Gundert-Remy U. 2005. Acute inhalative exposure assessment: derivation of guideline levels with special regard to sensitive subpopulations and time scaling. Toxicology 214: 256-267.
62. Mielke H, Gundert-Remy U. 2009. Bisphenol A levels in blood depend on age and exposure. Toxicol. Lett. 190: 32-40.
63. Mörk AK, Johanson G. 2010. Chemical-specific adjustment factors for intraspecies variability of acetone toxicokinetics using a probabilistic approach. Toxicol. Sci. 116: 336-348.
64. Naumann BD, Silverman KC, Dixit R, Faria EC, Sargent EV. 2001. Case studies for catergorical data-derived adjustment factors. Hum. Ecol. Risk Assess. 7: 61-105.
65. Neafsey P, Ginsberg G, Hattis D, Johns DO, Guyton KZ, Sonawane B. 2009. Genetic polymorphism in CYP2E1: Population distribution of CYP2E1 activity. J. Toxicol. Environ. Health B 12: 362-388.
66. Nong A, Krishnan K. 2007. Estimation of interindividual pharmacokinetic variability factor for inhaled volatile organic chemicals using a probability-bounds approach. Regul. Toxicol. Pharmacol. 48: 93-101.
67. Nong A, McCarver DG, Hines RN, Krishnan K. 2006. Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: a case study with toluene. Toxicol. Appl. Pharmacol. 214: 78-87.
68. Pelekis M, Krewski D, Krishnan K. 1997. Physiologically based algebraic expressions for predicting steady-state toxicokinetics of inhaled vapors. Toxicol. Methods 7: 205-225.
69. Pelekis M, Gephart LA, Lerman SE. 2001. Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds. Regul. Toxicol. Pharmacol. 33: 12-20.
70. Pelekis M, Nicolich MJ, Gauthier JS. 2003. Probabilistic framework for the estimation of the adult and child toxicokinetic intraspecies uncertainty factors. Risk Anal. 23: 1239-1255.
71. Price PS, Keenan RS, Schwab B. 1999. Defining the interindividual (intraspecies) uncertainty factor. Hum. Ecol. Risk Assess. 5: 1023-1033.
72. Price K, Haddad S, Krishnan K. 2003a. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children. J. Toxicol. Environ. Health A 66: 417-433.
73. Price PS, Conolly RB, Chaisson CF, Gross EA, Young JS, Mathis ET, Tedder DR. 2003b. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit. Rev. Toxicol. 33: 469-503.
74. Punt A, Jeurissen SM, Boersma MG, Delatour T, Scholz G, Schilter B, van Bladeren PJ, Rietjens IM. 2010. Evaluation of human interindividual variation in bioactivation of estragole using physiologically based biokinetic modeling. Toxicol. Sci. 113: 337-348.
75. Renwick AG. 1991. Safety factors and establishment of acceptable daily intakes. Food Addit. Contam. 8: 135-149.
76. Renwick AG. 1993. Data-derived safety factors for the evaluation of food additives and environmental contaminants. Food Addit. Contam. 10: 275-305.
77. Renwick AG, Lazarus NR. 1998. Human variability and noncancer risk assessment-an analysis of the default uncertainty factor. Regul. Toxicol. Pharmacol. 27: 3-20.
78. Sarangapani R, Gentry PR, Covington TR, Teeguarden JG, Clewell HJ, III. 2003. Evaluation of the potential impact of age- and gender-specific lung morphology and ventilation rate on the dosimetry of vapors. Inhal. Toxicol. 15: 987-1016.
79. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270: 414-423.
80. Silverman KC, Naumann BD, Holder DJ, Dixit R, Faria EC, Sargent EV, Gallo MA. 1999. Establishing Data-Derived Adjustment Factors from Published Pharmaceutical Clinical Trial Data. Human and Ecological Risk Assessment: An International Journal 5: 1059-1089.
81. Skowronski GA, Abdel-Rahman MS. 2001. Relevance of the 10X uncertainty factor to the risk assessment of drugs used by children and geriatrics. Hum. Ecol. Risk Assess. 7: 139-152.
82. Sonnier M, Cresteil T. 1998. Delayed ontogenesis of CYP1A2 in the human liver. Eur. J Biochem 251: 893-898.
83. Statistics Canada. 2003. Canadian community health survey, cycle 2.1. www.statcan.gc.ca/cgi-bin/imdb/p2SV.pl?Function=getSurvey&SurvId=3226&SurvVer=0&SDDS=3226&InstaId=15282&InstaVer=2&lang=en&db=imdb&adm=8&dis=2.
84. er juillet 2010, Canada. http://www.statcan.gc.ca/daily-quotidien/100929/t100929b4-fra.htm.
85. Stern AH, Clewell HJ, Swartout J. 2002. An objective uncertainty factor adjustment for methylmercury pharmacokinetic variability. Hum. Ecol. Risk Assess. 8: 885-894.
86. Suh DH, Abdel-Rahman MS. 2002. Evaluating the 10X uncertainty factor for children and elderly with data-derived values for neuromuscular blocking agents. Hum. Ecol. Risk Assess. 8: 841-858.
87. Tan YM, Liao KH, Clewell HJ, III. 2007. Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling. J. Expo. Sci. Environ. Epidemiol. 17: 591-603.
88. Tardif R, Droz PO, Charest-Tardif G, Pierrehumbert G, Truchon G. 2002. Impact of human variability on the biological monitoring of exposure to toluene: I. Physiologically based toxicokinetic modelling. Toxicol. Lett. 134: 155-163.
89. Teeguarden JG, Housand CJ, Smith JN, Hinderliter PM, Gunawan R, Timchalk CA. 2013. A multi-route model of nicotine-cotinine pharmacokinetics, pharmacodynamics and brain nicotinic acetylcholine receptor binding in humans. Regul. Toxicol. Pharmacol. 65: 12-28.
90. US EPA. 2002. A review of the reference dose and reference concentration process. Risk Assessment Forum (ed.). Document no. EPA/630/P-02/002F US Environmental Protection Agency. Washington DC.
91. Valcke M, Krishnan K. 2009. Physiologically Based Pharmacokinetic Modeling in the Risk assessment of Developmental Toxicants. In Developmental Toxicology, Hansen DK, Abbott BD (eds). Informa Health Care: New York; 243-274.
92. Valcke M, Krishnan K. 2010. An assessment of the interindividual variability of internal dosimetry during multi-route exposure to drinking water contaminants. Int. J. Environ. Res. Public Health 7: 4002-4022.
93. Valcke M, Krishnan K. 2011a. Evaluation of the impact of the exposure route on the human kinetic adjustment factor. Regul. Toxicol. Pharmacol. 59: 258-269.
94. Valcke M, Krishnan K. 2011b. An assessment of the impact of physico-chemical and biochemical characteristics on the human kinetic adjustment factor for systemic toxicants. Toxicology 286: 36-47.
95. Valcke M, Krishnan K. 2011c. Assessing the impact of the duration and intensity of inhalation exposure on the magnitude of the variability of internal dose metrics in children and adults. Inhal. Toxicol. 23: 863-877.
96. Valcke M, Krishnan K. 2013. Assessing the impact of child/adult differences in hepatic first-pass effect on the human kinetic adjustment factor for ingested toxicants. Regul. Toxicol. Pharmacol. 65: 126-134.
97. Valcke M, Nong A, Krishnan K. 2012. Modeling the human kinetic adjustment factor for inhaled volatile organic chemicals: whole population approach versus distinct subpopulation approach. J. Toxicol. doi:10.1155/2012/404329
98. Walker K, Hattis D, Russ A, Sonawane B, Ginsberg G. 2007. Approaches to acrylamide physiologically based toxicokinetic modeling for exploring child-adult dosimetry differences. J. Toxicol. Environ. Health A 70: 2033-2055.
99. WHO/IPCS. 2006. Principles for Evaluating Health Risks in Children Associated with Exposure to Chemicals. World Health Organization: Geneva.
100. WHO/IPCS. 2005. Chemical-Specific Adjustment Factors (CSAFs) for Interspecies Differences and Human Variability: Guidance Document for the Use of Data in Dose/Concentration-Response Assessment. World Health Organization: Geneva.
101. Yokley K, Tran HT, Pekari K, Rappaport S, Riihimaki V, Rothman N, Waidyanatha S, Schlosser PM. 2006. Physiologically-based pharmacokinetic modeling of benzene in humans: a Bayesian approach. Risk Anal. 26: 925-943.
102. Zeise L, Bois FY, Chiu WA, Hattis D, Rusyn I, Guyton KZ. 2013. Addressing human variability in next-generation human health risk assessments of environmental chemicals. Environ. Health Perspect. 121: 23-31.